John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema (DMO) in clinical practice. They discuss the half-life of aflibercept in wet age-related macular degeneration and its implications for drug durability. They explore the potential for more frequent dosing of aflibercept for DMO, with a focus on safety monitoring and the use of adjuvant steroids.
See the key takeaways below, and listen to the full podcast for all the clinical pearls.
Considering aflibercept half-life and higher molar dose in ophthalmology.
Using aflibercept for DMO, with focus on dosing and response variability.
Using higher doses of aflibercept for DMO, with potential for more frequent dosing.